Alto Neuroscience GAAP EPS of -$2.19 beats by $0.06 [Seeking Alpha]
Alto Neuroscience, Inc. (ANRO)
Company Research
Source: Seeking Alpha
Cash Position: As of December 31, 2025, the company had cash, cash equivalents, and restricted cash of approximately $177 million, compared to approximately $169 million in cash, cash equivalents, and restricted cash as of December 31, 2024. The company expects its cash balance to support planned operations into 2028. Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. Subscribe to Stock Ideas Sign Up More on Alto Neuroscience Seeking Alpha's Quant Rating on Alto Neuroscience Historical earnings data for Alto Neuroscience Financial information for Alto Neuroscience
Show less
Read more
Impact Snapshot
Event Time:
ANRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANRO alerts
High impacting Alto Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
ANRO
News
- Alto Neuroscience (ANRO) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ANRO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "holdMarketBeat
- Alto Neuroscience (ANRO) had its price target raised by Robert W. Baird from $22.00 to $41.00. They now have an "outperform" rating on the stock.MarketBeat
- Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.MarketBeat
- Alto Neuroscience (ANRO) had its price target raised by Wedbush from $13.00 to $22.00. They now have a "neutral" rating on the stock.MarketBeat
- Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
ANRO
Earnings
- 3/16/26 - Miss
ANRO
Sec Filings
- 3/16/26 - Form 8-K
- 3/16/26 - Form S-8
- 3/16/26 - Form 10-K
- ANRO's page on the SEC website